TABLE 1.
Characteristics of the cohort
| Parameter | 16S cohort (n = 19) | Pre/post-ETI P. aeruginosa metagenome subset (n = 7 of 19) | Non-ETI P. aeruginosa metagenome cohort (n = 7) | |
|---|---|---|---|---|
| Median age on enrollment, years (range) | 33.8 (21.9–48) | 32.2 (26.2–48) | 26.4 (21.2–49.7) | |
| Male, no. (%) | 8/19 (42.1) | 3/7 (42.9) | 4/7 (57.1) | |
| CFTR genotype, no. (%) | ||||
| ΔF508 homozygous | 12/19 (63.2) | 5/7 (71.4) | 1/7 (14.3) | |
| ΔF508/other | 7/19 (36.8) | 2/7 (28.6) | 5/7 (71.4) | |
| Unknown | -- | -- | 1/7 (14.3) | |
| BMI on enrollment (range) | 22.3 (17–35.9) | 22.5 (17.1–35.9) | 21.1 (18.7–34.9) | |
| ppFEV1 on enrollment (range) | 56 (21–103) | 43 (21–71) | 71 (30–110) | |
| FESS prior to enrollment (range)a | 14/19 (73.7) | 5/7 (71.4) | 7/7 (100) | |
| Transplant prior to enrollment (range) | 1/19 (5.3) | 0/7 (0) | 1/7 (14.3) | |
| No. (%) using modulator upon enrollment | ||||
| Ivacaftor | 1/19 (5.3) | 1/7 (14.3) | 1/7 (14.3) | |
| Orkambi | 1/19 (5.3) | 1/7 (14.3) | 0/7 (0) | |
| Symdeko | 2/19 (10.5) | 1/7 (14.3) | 0/7 (0) | |
| Days from enrollment to ETI prescription, median (range) | 608 (1–875) | 671 (48–840) | -- | |
| Days from ETI prescription to post-ETI sample, median (range) | 372 (15–566) | 342 (15–566) | -- | |
| Days from enrollment to last P. aeruginosa metagenome, median (range) | -- | 1,099 (348–1,245) | 624 (266–798) | |
a
FESS = functional endoscopic sinus surgery.